Date: 2021-05-25

Type of information: Nomination

Compound: chief medical officer chief operating officer

Company: Vectivbio (Switzerland)

Therapeutic area:

Type agreement: nomination

Action mechanism:



  • On May 25, 2021, VectivBio, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, announced the appointment of  Omar Khwaja, M.D., Ph.D., as Chief Medical Officer. Prior to joining Vectiv, Dr. Khwaja served as Chief Medical Officer and Head of Research and Development at Voyager Therapeutics, a biotechnology company focused on severe neurological diseases. Previously, he was the Global Head of Rare Diseases and Neuroscience Translational Medicine at Roche, where he worked for over eight years. Preceding Dr. Khwaja’s industry experience in drug development, he practiced medicine and taught in academia for over a decade, including as Director of the Clinical Neurogenetics program at Boston Children’s Hospital and as a member of the faculty at Harvard Medical School. Dr. Khwaja received his M.D. and Ph.D. in Human Molecular Genetics from the University of Cambridge. He is a member of the Royal College of Physicians, serves as the Chief Medical Officer for the Spinal Muscular Atrophy Foundation and is the Chair of the Scientific Advisory Board of the CDKL5 Forum.
  • Concurrently, Christian Meyer, M.D., Ph.D., has been appointed to the newly created position of Chief Operating Officer. Dr. Meyer was part of the founding team of VectivBio, acting as its Chief Development Officer since June 2019, after serving as Chief Medical Officer of both Therachon AG and uniQure N.V., where he led the development of several rare disease programs and established their development organizations. Prior to his role at uniQure, he held several senior executive positions at Cardoz AB, Symphogen A/S and Zymenex A/S, where he was responsible for leading clinical development in the rare disease space. Dr. Meyer began his career at Novo Nordisk A/S and held academic and hospital positions before entering the pharmaceutical industry. Dr. Meyer received his M.D. and Ph.D. in Clinical Cardiology from the University of Copenhagen.

Financial terms:

Latest news:

Is general: Yes